Marla Persky, a director at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), executed a significant transaction on June 3, 2026, by selling 15,500 shares of the company's common stock. The total value of this sale was $91,432, with shares transacted at a weighted average price of $5.8989. Individual transaction prices for this sale ranged between $5.810 and $5.960 per share. This sale was carried out under a Rule 10b5-1 trading plan, which Persky adopted on June 12, 2025. At the time of the sale, Xeris shares were trading at $6.18, and the company held a market capitalization of $1.06 billion.
According to InvestingPro analysis, Xeris Biopharma appears undervalued relative to its Fair Value, placing it among the opportunities on the platform's most undervalued stocks list. The biopharmaceutical company has demonstrated strong fundamentals, with revenue growth of 41% over the last twelve months and an impressive gross profit margin of 86%. InvestingPro Tips highlight that the company is profitable and net income is expected to grow this year. These insights are part of over 10 additional insights available to subscribers, along with a comprehensive Pro Research Report.
On June 4, 2026, the day after the sale, Persky acquired 24,193 shares of common stock through a restricted stock unit (RSU) grant. These shares were granted under the company's 2018 Stock Option and Incentive Plan and will vest in full upon the earlier of June 4, 2026, or the date of the company's next annual meeting of stockholders, contingent on continued service. Additionally, on June 4, 2026, Persky received a grant of 32,996 stock options, allowing her to purchase an equivalent number of common shares at an exercise price of $6.15 per share. These options, granted under the same 2018 Plan, are set to vest in full upon the earlier of June 4, 2026, or the date of the company's next annual meeting of stockholders, subject to continued service. The options have an expiration date of June 4, 2036.
Following these transactions, Persky directly holds 150,693 shares of Xeris Biopharma common stock. She also directly holds 32,996 stock options. Additionally, 6,370 shares of common stock are held indirectly through the Marla Susan Persky Revocable Trust, for which Persky disclaims beneficial ownership except to the extent of her pecuniary interest.
In other recent news, Xeris Biopharma reported strong financial results for the first quarter of 2026. The company achieved a 38% increase in total revenue compared to the previous year, reaching $83.1 million. Although this figure slightly missed revenue forecasts, Xeris Biopharma exceeded earnings expectations with an earnings per share (EPS) of $0.01. These developments were well-received in the market. Additionally, analysts from various firms have been closely monitoring the company's performance. While some analysts have shared optimistic views, specific upgrades or downgrades were not detailed in the recent reports. These developments reflect the company's ongoing financial momentum.